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Objectives In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel
in non–ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and
clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients.
Background Clopidogrel, in combination with aspirin, reduces cardiovascular events in patients with acute coronary syn-
dromes (ACS). However, patients with poor inhibition of platelet aggregation with clopidogrel may be less well
protected. AZD6140 is a reversible oral P2Y12 receptor antagonist that has been studied in ACS patients in com-
parison with clopidogrel (DISPERSE-2 study).
Methods Patients were randomized to receive either AZD6140 90 mg twice a day, AZD6140 180 mg twice a day, or
clopidogrel 75 mg once a day for up to 12 weeks in a double-blind, double-dummy design. One-half the patients
allocated AZD6140 received a 270-mg loading dose. Patients randomized to receive clopidogrel were given a
300-mg loading dose unless they had already been treated with clopidogrel. Adenosine diphosphate-induced
platelet aggregation was assessed by optical aggregometry on day 1 and at 4-week intervals.
Results AZD6140 inhibited platelet aggregation in a dose-dependent fashion and both doses achieved greater levels of
inhibition than clopidogrel (e.g., 4 weeks, 4-h postdose [mean (SD)]: clopidogrel 64% [22%], AZD6140 90
mg 79% [22%], AZD6140 180 mg 95% [8%]. AZD6140 also produced further suppression of platelet aggre-
gation in patients previously treated with clopidogrel.
Conclusions AZD6140 exhibited greater mean inhibition of platelet aggregation than a standard regimen of clopidogrel in ACS
patients. In addition, AZD6140 further suppressed platelet aggregation in clopidogrel pretreated patients.
(J Am Coll Cardiol 2007;50:1852–6) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058p
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November 6, 2007:1852–6 Effect of AZD6140 on Platelet Aggregation in ACShromboxane A2. However, this positive feedback loop plays
limited role in platelet reactivity to soluble platelet agonists
2), so that, although aspirin is effective in reducing the
ncidence of thromboembolic complications of ACS, a
ubstantial risk of arterial thromboembolism remains (3).
Clopidogrel is a thienopyridine antiplatelet agent that is
nactive until absorbed and converted to its active metabolite
y hepatic cytochrome P450 enzymes (4). This active
etabolite binds irreversibly to platelet P2Y12 receptors,
hich play a major role in amplifying the platelet responses
hat underlie arterial thrombosis and associated inflamma-
ion (2). The addition of clopidogrel to aspirin in the
anagement of ACS yields greater protection against arte-
ial thromboembolic events than aspirin alone (5). However,
ome patients have little detectable response to clopi-
ogrel therapy and appear to have a higher risk of major
dverse cardiac events (6 –9).
AZD6140 is a novel oral P2Y12 receptor antagonist that
inds reversibly to the P2Y12 receptor, antagonizing the
inding of adenosine diphosphate (ADP) (10). AZD6140
oes not require metabolic activation, although the major
etabolite, AR-C124910XX, is also active (data on file,
straZeneca). A phase IIa study in patients with stable
therosclerotic disease showed that AZD6140 yielded greater
ean levels of inhibition of platelet aggregation than clopi-
ogrel, and the highest doses of AZD6140 yielded consistently
igh levels of inhibition (11). The DISPERSE (Dose confIr-
ation Study assessing anti-Platelet Effects of AZD6140 vs.
lopidogRel in non–ST-segment Elevation myocardial
nfarction)-2 study compared different dose regimens of
ZD6140 with clopidogrel in patients with non–ST-segment
levation ACS (12). We report here a substudy of
ISPERSE-2 assessing the pharmacodynamics and pharma-
okinetics of AZD6140 in comparison with clopidogrel.
ethods
tudy design. Full description of the methods may be
ound in the Online Appendix. In brief, this substudy of
ISPERSE-2 was performed in selected centers. Patients
ho had not received clopidogrel before randomization
“clopidogrel-naïve”) were studied separately from those who
ere currently receiving clopidogrel (“clopidogrel-pretreated”).
Patients were randomized to receive either AZD6140
0 mg twice a day (bid), AZD6140 180 mg bid, or
lopidogrel for 4, 8, or 12 weeks depending on the enroll-
ent phase. One-half the patients in each AZD6140 group
ere randomized to receive a loading dose of AZD6140 270
g. Patients randomized to receive clopidogrel were given a
oading dose of clopidogrel 300 mg if clopidogrel naïve or a
aintenance dose of 75 mg once daily (qd) if clopidogrel
retreated.
At the time points shown in the Results section, venous
lood samples were collected into lithium heparin for
harmacokinetic studies and into sodium citrate for platelet
ggregation studies. Optical aggregometry was performedsing ADP 20 mol/l as agonist.
ercentage aggregation was re-
orded as both the maximum
ggregation response and the fi-
al aggregation response 6 min
fter the addition of ADP.
tatistical analysis. Data are
resented as mean and standard
eviation. Statistical significance
as assigned to p values 0.05.
full description of the statisti-
al methods is found in the On-
ine Appendix.
esults
tudy population. Ninety-one patients were enrolled in
his substudy (57 male, 34 female; mean age 63 11 years),
f whom 89 received study medication and had evaluable
latelet aggregation data. Forty-five patients were clopi-
Figure 1 Randomization of Patients
Randomization of (A) clopidogrel-naïve patients and
(B) clopidogrel-pretreated patients. bid  twice daily; qd  once daily.
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
bid  twice-daily
administration
qd  once-daily
administration
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Effect of AZD6140 on Platelet Aggregation in ACS November 6, 2007:1852–6ogrel naïve and 44 patients were clopidogrel pretreated
Fig. 1).
latelet aggregation in clopidogrel-naïve patients. AZD6140
nhibited platelet aggregation in a dose-dependent manner (Fig.
). Levels of inhibition seen with all AZD6140 doses were greater
han the maximum level of inhibition seen after the clopidogrel
oading dose (p 0.001 for all AZD6140 groups vs. clopidogrel
t 4 h, final aggregation response). In order to illustrate interindi-
idual variability in responses, individual data are presented as area
nder the curve (Fig. 3). On day 1, a consistently high response
as seen with AZD6140 270 mg, and only a few individuals
eceiving clopidogrel had a similar response.
Inhibition of platelet aggregation by AZD6140 re-
ained stable at 4 weeks (Fig. 4), and the most consistent
esponse was seen with AZD6140 180 mg (Fig. 3B).
Figure 2 Inhibition of Platelet Aggregation After
Initial Doses of Clopidogrel and AZD6140
Mean percentage inhibition of platelet aggregation derived from (A) maximum
aggregation response and (B) final aggregation response at 6 min after addi-
tion of adenosine diphosphate 20 mol/l, for clopidogrel-naïve patients before
and after clopidogrel 300 mg (n  14), AZD6140 90 mg (n  9), AZD6140
180 mg (n  7), or AZD6140 270 mg (n  15). Error bars show standard
deviation and points are nudged on the X axis only to reveal error bars. *p 
0.05 for AZD6140 versus clopidogrel.nhibition by clopidogrel remained lower than eitherZD6140 group (e.g., p  0.12, 0.04, and 0.002 for
lopidogrel vs. AZD6140 90 mg at 4, 8, and 12 weeks,
espectively, and p  0.004, 0.017, and 0.004 for clopi-
ogrel vs. AZD6140 180 mg, respectively, 4 h post-dose,
nal response).
latelet aggregation in clopidogrel-pretreated patients.
he mean (standard deviation) baseline level of platelet
ggregation in the group of patients allocated to receive
urther clopidogrel 75 mg qd was 38% (15%, final re-
ponse) and changed little at 4 h (36% [17%], final
esponse), whereas each of the AZD6140 doses produced
ubstantial further inhibition of platelet aggregation in a
ose-dependent fashion (Fig. 5). This substantial inhibition
y AZD6140 occurred regardless of the baseline aggrega-
Figure 3 Individual Responses to Clopidogrel and AZD6140
Individual area-under-the-curve data for inhibition of platelet aggregation derived
from final aggregation response at 6 min after addition of ADP 20 mol/l, for
clopidogrel-naïve patients (A) after the first dose of either clopidogrel 300 mg,
AZD6140 90 mg, AZD6140 180 mg, or AZD6140 270 mg and (B) after 4
weeks of treatment and after next dose of either clopidogrel 75 mg, AZD6140
90 mg, or AZD6140 180 mg. Data are for the first 8 h of treatment but are
representative of the smaller numbers for whom data were available for the full
12 h. The lines indicate mean values. *p  0.05 for AZD6140 versus clopi-
dogrel. ADP  adenosine diphosphate; IPA  inhibition of platelet aggregation;
other abbreviations as in Figure 1.
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November 6, 2007:1852–6 Effect of AZD6140 on Platelet Aggregation in ACSion response; the 12 patients in the highest tertile of
ggregation response at baseline (52.6% to 100%) that
eceived any dose of AZD6140 had a mean reduction in
latelet aggregation from 62.3% to 7.4%, compared with 10
atients in the lowest tertile of aggregation response at
aseline (0% to 35.5%), who had a mean reduction in
latelet aggregation from 19.3% to 2.2%.
harmacokinetics of AZD6140 and its active major
etabolite, AR-C124910XX. Mean levels of AZD6140
ere highest at the 2-h time point whereas mean levels of
he active metabolite AR-C124910XX peaked at 2 to 4 h
ith levels 2- to 5-fold lower than those of AZD6140.
harmacokinetic parameters are shown in the Online
Figure 4 Steady-State and 24 h Postdose Inhibition of
Platelet Aggregation by Clopidogrel and AZD6140
Mean percentage inhibition of platelet aggregation both after 4 weeks of study
medication (clopidogrel-naïve patients) and 24 h after discontinuation of study
medication derived from (A) maximum aggregation response and (B) final
aggregation response at 6 min after addition of adenosine diphosphate 20
mol/l, before and after the next dose of either clopidogrel 75 mg (n  10),
AZD6140 90 mg (n  15), or AZD6140 180 mg (n  10). Error bars show
standard deviation and points are nudged on the X axis only to reveal error
bars. *p  0.05 for AZD6140 versus clopidogrel; †p  0.05 for clopidogrel
predose versus 2 h postdose.ppendix.iscussion
his substudy of DISPERSE-2 is the first study to assess
he pharmacodynamic effects of a reversible oral P2Y12
eceptor antagonist in patients with ACS. All initial doses
f AZD6140 achieved greater inhibition of platelet aggre-
ation than a 300-mg loading dose of clopidogrel, providing
rationale for further studies assessing whether AZD6140
ffers superior efficacy in protecting against thromboembolic
vents in patients with ACS.
Some patients respond poorly to clopidogrel, even when
higher loading dose of 600 mg is employed, although this
igher dose does reduce the proportion of patients exhibit-
ng a poor response in the early phase of treatment (13).
lthough we did not study a 600-mg loading dose of
lopidogrel and would expect to have seen higher levels of
nhibition in the first day of treatment with this higher
oading dose, a previous study has suggested that levels of
nhibition after 48 h are similar to those achieved with a
00-mg loading dose followed by maintenance therapy (14).
e found in this study that the clopidogrel 75-mg daily
aintenance dose achieves an increase in inhibition 4 h
ostdose at steady state, as seen at the 4-week time point.
his may relate to the fact that clopidogrel is metabolized
apidly to its inactive carboxyl metabolite, and new platelets
eleased into the circulation after clopidogrel is metabolized
n this way will not be exposed to active metabolite of
lopidogrel until the next dose is given. This is different
rom the dynamics of inhibition by AZD6140, which is
onstantly present in the plasma and so will continue to
nhibit new platelets as they are released, to an extent
Figure 5 Suppression of Platelet Aggregation by
AZD6140 in Clopidogrel-Pretreated Patients
Mean percentage platelet aggregation derived from final aggregation response
at 6 min after addition of adenosine diphosphate 20 mol/l, for clopidogrel-
pretreated patients before and after either clopidogrel 75 mg (n  12) or the
first dose of AZD6140 90 mg (n  9), AZD6140 180 mg (n  7), or AZD6140
270 mg (n  16). Error bars show standard deviation and points are nudged
on the X axis only to reveal error bars. *p  0.05 for AZD6140 versus
clopidogrel.
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nd its active metabolite.
This study also demonstrates that treatment with
ZD6140 leads to further inhibition of platelet aggregation
n those patients who are already receiving treatment with
lopidogrel, even in those patients who have the highest
latelet aggregation response on clopidogrel alone. This is
onsistent with blockade of P2Y12 receptors by AZD6140
hat are not blocked by clopidogrel therapy and supports the
ssumption that AZD6140 can address the problem of high
latelet reactivity in patients treated with clopidogrel.
onclusions
ZD6140 yields greater and more consistent inhibition of
latelet aggregation, in a dose-dependent and reversible
ashion, than a standard regimen of clopidogrel in patients
ith non–ST-segment elevation ACS and, furthermore,
dditionally suppresses platelet aggregation in patients cur-
ently receiving clopidogrel. These characteristics of
ZD6140 may yield benefits in clinical practice; this will
e explored in a large, ongoing outcomes trial in patients
ith ST-segment elevation and non–ST-segment eleva-
ion ACS.
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